Security key
19249H103
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS)
CUSIP: 19249H103
Q2 2017 13F Holders as of 30 Jun 2017
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 40,123,971
- Total 13F value
- $575,784,532
- Share change
- +3,042,713
- Put/Call ratio
- 39%
- SEC-reported price per share
- $14.35
- Number of holders
- 105
- Value change
- +$26,148,562
- Number of buys
- 72
- Number of sells
- 43
- Shares outstanding
- 153,624,096
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2017
Institutions
105
Top holders
10
CHRS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2017
Previous quarter: Q1 2017
Coherus Oncology, Inc. SEC filings
Coherus Oncology, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 19249H103
Recent filing periods:
Ownership snapshot
Top reported holders of CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Mar 2017
13F
Lead comparable stake: 5%
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
5%
Kohlberg Kravis Roberts & Co. L.P.
2%
BlackRock Finance, Inc.
1.9%
VANGUARD GROUP INC
1.4%
JPMORGAN CHASE & CO
1.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
Company
|
5%
|
$162,262,000
7,671,981 shares
|
— | 31 Mar 2017 |
| Kohlberg Kravis Roberts & Co. L.P. |
13F
Company
|
2%
|
$64,614,000
3,055,055 shares
|
— | 31 Mar 2017 |
| BlackRock Finance, Inc. |
13F
Company
|
1.9%
|
$60,168,000
2,844,827 shares
|
— | 31 Mar 2017 |
| VANGUARD GROUP INC |
13F
Company
|
1.4%
|
$46,726,000
2,209,244 shares
|
— | 31 Mar 2017 |
| JPMORGAN CHASE & CO |
13F
Company
|
1.1%
|
$34,485,000
1,630,487 shares
|
— | 31 Mar 2017 |
| PFM Health Sciences, LP |
13F
Company
|
0.98%
|
$31,718,000
1,499,682 shares
|
— | 31 Mar 2017 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2017
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
105
Shares
40,123,971
Rows available
105
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2017 vs Q1 2017 Across Filers
Q1 2017 holders
109
Q2 2017 holders
105
Holder diff
-4
| Investor | Q1 2017 Shares | Q2 2017 Shares | Share Diff | Share Chg % | Q1 2017 value | Q2 2017 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend